NME Goal Dates Sparse In Late 2007: Third Year Of Low NME Count Likely
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Only three NDAs for new molecular entities have user fee goal dates in the remainder of 2007, which implies a marked slow-down in the pace of NME actions after FDA’s busy October.
You may also be interested in...
Pharmacyclics Xcytrin Is "Not Approvable" For Brain Metastases
Pharmacyclics' anti-cancer product Xcytrin (motexafin gadolinium) received a "not approvable" letter, closing the current chapter in a year-long fight to get the drug approved
Remaining Candidates For the NME Class of 2007
Remaining Candidates For The NME Class Of 2007
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.